161890.KS
Kolmar Korea Co., Ltd. [161890.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
161890.KS Stock Summary
Top 10 Correlated ETFs
161890.KS
Top 10 Correlated Stocks
161890.KS
In the News
161890.KS Financial details
Company Rating
Neutral
Market Cap
1180.26B
Income
5.19B
Revenue
2155.68B
Book val./share
28347.41
Cash/share
12248.58
Dividend
-
Dividend %
-
Employees
1.07K
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
268.28
Forward P/E
-
PEG
-11.84
P/S
0.61
P/B
1.81
P/C
4.03
P/FCF
-79.11
Quick Ratio
-
Current Ratio
0.82
Debt / Equity
1.62
LT Debt / Equity
0.14
-
-
EPS (TTM)
226.91
EPS next Y
-
EPS next Q
-
EPS this Y
-226.6%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-29.3%
Revenue last 5Y
6.95%
Revenue Q/Q
6.88%
EPS Q/Q
-508.14%
-
-
-
-
SMA20
10.75%
SMA50
-1.15%
SMA100
4.31%
Inst Own
-
Inst Trans
-
ROA
-
ROE
1%
ROC
0.04%
Gross Margin
26%
Oper. Margin
4%
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
37450.0-60700.0
52W High
-18.62%
52W Low
+31.91%
RSI
55
Rel Volume
0.97
Avg Volume
139.24K
Volume
134.95K
Perf Week
-1.2%
Perf Month
7.63%
Perf Quarter
-9.85%
Perf Half Y
-5.36%
-
-
-
-
Beta
0.655
-
-
Volatility
805.97%, 2560.22%
Prev Close
-2.18%
Price
49400
Change
-1%
161890.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 68.11K | 57.78K | 69.33K | 81.54K | 94.21K | |
| Net income per share | 1.28K | 7K | 1.57K | -179.23 | 226.9 | |
| Operating cash flow per share | 7.29K | 5.31K | -136.48 | 3.97K | 4.93K | |
| Free cash flow per share | 3.96K | -69.42 | -2.38K | 1.46K | -522.03 | |
| Cash per share | 10.42K | 16.78K | 18.54K | 13K | 12.25K | |
| Book value per share | 20.84K | 27.26K | 29.88K | 29.02K | 28.35K | |
| Tangible book value per share | -12.84K | -4.16K | 10.17K | 7.33K | 6.45K | |
| Share holders equity per share | 20.84K | 27.26K | 29.88K | 29.02K | 28.35K | |
| Interest debt per share | 56.71K | 51.05K | 41.07K | 48.05K | 47.96K | |
| Market cap | 1068.89B | 1164.65B | 920.97B | 934.7B | 1224.14B | |
| Enterprise value | 2179.7B | 1918.3B | 1638.88B | 1781.42B | 2156.14B | |
| P/E ratio | 36.78 | 7.27 | 25.72 | -227.92 | 235.78 | |
| Price to sales ratio | 0.69 | 0.88 | 0.58 | 0.5 | 0.57 | |
| POCF ratio | 6.48 | 9.59 | -294.91 | 10.29 | 10.85 | |
| PFCF ratio | 11.94 | -733.18 | -16.9 | 28.02 | -102.48 | |
| P/B Ratio | 2.27 | 1.87 | 1.35 | 1.41 | 1.89 | |
| PTB ratio | 2.27 | 1.87 | 1.35 | 1.41 | 1.89 | |
| EV to sales | 1.41 | 1.45 | 1.03 | 0.95 | 1 | |
| Enterprise value over EBITDA | 11.77 | 5.59 | 10.27 | 11.37 | 9.36 | |
| EV to operating cash flow | 13.22 | 15.79 | -524.8 | 19.62 | 19.12 | |
| EV to free cash flow | 24.36 | -1.21K | -30.08 | 53.4 | -180.51 | |
| Earnings yield | 0.03 | 0.14 | 0.04 | 0 | 0 | |
| Free cash flow yield | 0.08 | 0 | -0.06 | 0.04 | -0.01 | |
| Debt to equity | 2.61 | 1.81 | 1.33 | 1.61 | 1.62 | |
| Debt to assets | 0.51 | 0.45 | 0.35 | 0.36 | 0.35 | |
| Net debt to EBITDA | 6 | 2.2 | 4.5 | 5.41 | 4.04 | |
| Current ratio | 0.91 | 1.13 | 0.99 | 0.94 | 0.7 | |
| Interest coverage | 2.21 | 7.55 | 2.75 | 2.24 | 3.03 | |
| Income quality | 4.9 | 0.76 | -0.07 | -22.14 | 21.72 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | |
| Payout ratio | 0.25 | 0.05 | 0.22 | -3.62 | 2.63 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Intangibles to total assets | 0.47 | 0.44 | 0.43 | 0.44 | 0.42 | |
| Capex to operating cash flow | -0.46 | -1.01 | 16.45 | -0.63 | -1.11 | |
| Capex to revenue | -0.05 | -0.09 | -0.03 | -0.03 | -0.06 | |
| Capex to depreciation | -1.24 | -1.99 | -0.88 | -0.76 | -1.33 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 24.54K | 65.54K | 32.44K | 10.82K | 12.03K | |
| ROIC | 0.04 | 0.1 | 0.03 | -0.01 | 0.05 | |
| Return on tangible assets | 0.02 | 0.11 | 0.02 | 0 | 0 | |
| Graham Net | -46.54K | -37.27K | -23.31K | -36.6K | -40.47K | |
| Working capital | -61.4B | 88.4B | -5.7B | -51.84B | -385.33B | |
| Tangible asset value | -290.57B | -95.2B | 232.67B | 167.67B | 147.59B | |
| Net current asset value | -906.42B | -715.13B | -363.6B | -647.54B | -692.48B | |
| Invested capital | 2.61 | 1.81 | 1.33 | 1.61 | 1.62 | |
| Average receivables | 232.5B | 241.81B | 242.03B | 262.17B | 302.4B | |
| Average payables | 112.47B | 105.06B | 126.98B | 158.6B | 175.32B | |
| Average inventory | 168.75B | 154.63B | 179.38B | 224.79B | 260.16B | |
| Days sales outstanding | 57.97 | 65.95 | 56.41 | 54.62 | 55.13 | |
| Days payables outstanding | 37.27 | 39.49 | 49.49 | 41.85 | 42.97 | |
| Days of inventory on hand | 52.9 | 60.55 | 66.23 | 62.55 | 63.38 | |
| Receivables turnover | 6.3 | 5.53 | 6.47 | 6.68 | 6.62 | |
| Payables turnover | 9.79 | 9.24 | 7.38 | 8.72 | 8.49 | |
| Inventory turnover | 6.9 | 6.03 | 5.51 | 5.83 | 5.76 | |
| ROE | 0.06 | 0.26 | 0.05 | -0.01 | 0.01 | |
| Capex per share | -3.33K | -5.38K | -2.24K | -2.51K | -5.45K |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 20.94K | 21.31K | 26.21K | 22.57K | 24.12K | |
| Net income per share | -2.07K | 254.45 | 1.52K | 502.14 | -2.05K | |
| Operating cash flow per share | 1.74K | -797.63 | 1.46K | 1.62K | 2.65K | |
| Free cash flow per share | 1.18K | -1.71K | -791.01 | 898.65 | 1.09K | |
| Cash per share | 13K | 11.87K | 10.97K | 11.77K | 12.25K | |
| Book value per share | 29.02K | 28.64K | 30.29K | 30.78K | 28.35K | |
| Tangible book value per share | 7.33K | 6.86K | 8.86K | 9.84K | 6.45K | |
| Share holders equity per share | 29.02K | 28.64K | 30.29K | 30.78K | 28.35K | |
| Interest debt per share | 47.06K | 47.75K | 49.43K | 49.21K | 46.54K | |
| Market cap | 934.7B | 958.72B | 1006.77B | 1169.23B | 1224.14B | |
| Enterprise value | 1781.42B | 1847.8B | 1964.96B | 2118.52B | 2156.14B | |
| P/E ratio | -4.94 | 41.17 | 7.24 | 25.44 | -6.53 | |
| Price to sales ratio | 1.95 | 1.97 | 1.68 | 2.26 | 2.22 | |
| POCF ratio | 23.49 | -52.53 | 30.2 | 31.48 | 20.22 | |
| PFCF ratio | 34.58 | -24.53 | -55.63 | 56.86 | 49.24 | |
| P/B Ratio | 1.41 | 1.46 | 1.45 | 1.66 | 1.89 | |
| PTB ratio | 1.41 | 1.46 | 1.45 | 1.66 | 1.89 | |
| EV to sales | 3.72 | 3.79 | 3.28 | 4.1 | 3.91 | |
| Enterprise value over EBITDA | 467 | 15.81 | 12.03 | 14.99 | 35.35 | |
| EV to operating cash flow | 44.77 | -101.24 | 58.94 | 57.03 | 35.61 | |
| EV to free cash flow | 65.9 | -47.27 | -108.57 | 103.03 | 86.74 | |
| Earnings yield | -0.05 | 0.01 | 0.03 | 0.01 | -0.04 | |
| Free cash flow yield | 0.03 | -0.04 | -0.02 | 0.02 | 0.02 | |
| Debt to equity | 1.61 | 1.66 | 1.62 | 1.58 | 1.62 | |
| Debt to assets | 0.36 | 0.36 | 0.37 | 0.37 | 0.35 | |
| Net debt to EBITDA | 221.97 | 7.61 | 5.87 | 6.72 | 15.28 | |
| Current ratio | 0.94 | 0.85 | 0.94 | 0.82 | 0.7 | |
| Interest coverage | -1.72 | 2.86 | 4.93 | 2.71 | 2.96 | |
| Income quality | -0.84 | -2.83 | 0.78 | 1.88 | -1.29 | |
| Dividend Yield | 0 | 0 | 0.02 | 0 | 0 | |
| Payout ratio | -0.07 | 0 | 0.48 | 0.26 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.21 | 0.18 | 0.21 | 0.01 | |
| Research and developement to revenue | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Intangibles to total assets | 0.44 | 0.43 | 0.43 | 0.43 | 0.42 | |
| Capex to operating cash flow | -0.32 | 1.14 | -1.54 | -0.45 | -0.59 | |
| Capex to revenue | -0.03 | -0.04 | -0.09 | -0.03 | -0.06 | |
| Capex to depreciation | -0.61 | -0.89 | -2.23 | -0.7 | -1.47 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 36.76K | 12.81K | 32.18K | 18.65K | 36.15K | |
| ROIC | -0.01 | 0.01 | 0.03 | 0.01 | 0.02 | |
| Return on tangible assets | -0.03 | 0 | 0.02 | 0.01 | -0.03 | |
| Graham Net | -36.6K | -38.19K | -38.59K | -37.62K | -40.47K | |
| Working capital | -51.84B | -151.64B | -58.56B | -191.94B | -385.33B | |
| Tangible asset value | 167.67B | 156.9B | 202.82B | 225.19B | 147.59B | |
| Net current asset value | -647.54B | -654.65B | -660.77B | -636.95B | -692.48B | |
| Invested capital | 1.61 | 1.66 | 1.62 | 1.58 | 1.62 | |
| Average receivables | 297.53B | 309.74B | 349.92B | 348.61B | 331.65B | |
| Average payables | 155.69B | 182.92B | 196.54B | 185.84B | 187.37B | |
| Average inventory | 246.96B | 253.53B | 265.9B | 271.12B | 279.51B | |
| Days sales outstanding | 52.45 | 62.81 | 53.95 | 58.85 | 53.1 | |
| Days payables outstanding | 39.42 | 49.92 | 38.65 | 44.21 | 42.28 | |
| Days of inventory on hand | 58.92 | 64.96 | 54.47 | 66.73 | 62.36 | |
| Receivables turnover | 1.72 | 1.43 | 1.67 | 1.53 | 1.69 | |
| Payables turnover | 2.28 | 1.8 | 2.33 | 2.04 | 2.13 | |
| Inventory turnover | 1.53 | 1.39 | 1.65 | 1.35 | 1.44 | |
| ROE | -0.07 | 0.01 | 0.05 | 0.02 | -0.07 | |
| Capex per share | -557.49 | -910.68 | -2.25K | -724.75 | -1.56K |
161890.KS Frequently Asked Questions
What is Kolmar Korea Co., Ltd. stock symbol ?
Kolmar Korea Co., Ltd. is a KR stock and trading under the symbol 161890.KS
What is Kolmar Korea Co., Ltd. stock quote today ?
Kolmar Korea Co., Ltd. stock price is $49400 today.
Is Kolmar Korea Co., Ltd. stock public?
Yes, Kolmar Korea Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 139.24K
- Market Capitalization 1180.26B
- Employee 1.07K
- CEO Mr. Hak-Hee Kang
- Headquarters Sejong City,KR
- IPO Date 2012-10-18
-
Website
https://www.kolmar.co.kr 
Kolmar Korea Co., Ltd. researches, develops, produces, and sells beauty and health products in South Korea and internationally. It offers various cosmetic products, including skin care, makeup, baby, hair care, and body care products, as well as perfume, functional cosmetics, and qusi drugs. The company also provides prescription, over-the-counter, and bioequivalent drugs; drugs for dermatology and circulatory system; ointment and external, and oral solutions; and oral solids. In addition, it offers health functional food comprising health supplements; ingredients; special purpose food; and individually recognized health supplements. The company was founded in 2012 and is headquartered in Sejong, South Korea.
